{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-22-000041","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.768741+00:00","generated_at":"2026-06-21T23:56:25.661313+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio reports Q3 net loss of $16.6M; cash $114.9M; SENTI-202 and SENTI-301A IND filings on track for 2023","bullets":["Net loss $16.6M ($0.38/share) for Q3 2022; R&D expenses $8.1M, G&A $10.8M.","Cash and equivalents $114.9M as of Sep 30, 2022; expected cash runway into 2024.","SENTI-202 IND on track for 2023; Phase 1 trial planned for CD33/FLT3+ hematologic malignancies including AML and MDS.","Selected SENTI-301A development candidate for GPC3+ solid tumors including HCC; IND expected in 2023.","Preclinical data for SENTI-301A and SENTI-401 presented at SITC; SENTI-202 data to be presented at ASH Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-22-000041","json":"https://secwatch.observer/filing/0001854270-22-000041.json","markdown":"https://secwatch.observer/filing/0001854270-22-000041.md","text":"https://secwatch.observer/filing/0001854270-22-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/0001854270-22-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/snti-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:56:25.661313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60e92eb07b94ebe82330d8bd5a8ebceadd63ad27","claim":"Senti Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Senti Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427022000041/0001854270-22-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}